Pipeline
Tilvestamab (BGB149)
Tilvestamab (BGB149) is a first-in-class, fully humanized, therapeutic anti-AXL function-blocking monoclonal antibody, discovered and developed by BerGenBio
Two Ph1 studies with tilvestamab have been completed in health volunteers and in serous ovarian cancer. Preclinical data have shown tilvestamab prevents AXL-mediated cell signaling in cancer models, reduces cell migration and invasion, and shows anti-tumor efficacy.
